<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="FLT3 signaling in disease" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">FLT3 is a type III receptor tyrosine kinase (RTK). The extracellular domain consists of 5 immunoglobulin (Ig) domains that contribute to dimerization and ligand binding. The intracellular region has a juxtamembrane domain that plays a role in autoinhibiting the receptor in the absence of ligand, and a bi-lobed kinase region with an activation loop and the catalytic cleft (reviewed in Klug et al, 2018). Signaling through FLT3 occurs after ligand-induced dimerization and transautophosphorylation, and promotes signaling through the MAP kinase, PI3K and STAT5 pathways, among others. FLT3 signaling promotes cellular proliferation and differentiation and contributes to haematopoeisis. FLT3 is mutated in up to 30% of acute myeloid leukemias. ~25% of the FLT3 mutations in AML cases occur as internal tandem duplications (ITDs) either in the juxtamembrane domain region encoded by exon 14 or the tyrosine kinase domain (TKD), while ~7-10% of AML cases contain FLT3 missense mutations in the TKD (reviewed in Klug et al, 2018; Daver et al, 2019). These mutations all support ligand-independent activation of the receptor and result in constitutive activation and signaling (Zheng et al, 2004; reviewed in Klug et al, 2018; Kazi and Roonstrand, 2019). In rare cases, the FLT3 locus is also subject to translocations that generate constitutively active fusion proteins (reviewed in Kazi and Roonstrand, 2019). Oncogenic FLT3 activity can be targeted with tyrosine kinase inhibitors, although resistance often arises due to secondary mutations or activation of bypass pathways (reviewed in Staudt et al, 2018; Daver et al, 2019).
 View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=9682385 Reactome].</Comment>
  <Comment Source="Reactome-Converter">Pathway is converted from Reactome ID: 9682385</Comment>
  <Comment Source="Reactome-version">Reactome version: 88</Comment>
  <Comment Source="Reactome Author">Reactome Author: Rothfels, Karen</Comment>
  <BiopaxRef>d64</BiopaxRef>
  <BiopaxRef>a5e</BiopaxRef>
  <BiopaxRef>fca</BiopaxRef>
  <BiopaxRef>cbf</BiopaxRef>
  <BiopaxRef>d3a</BiopaxRef>
  <Attribute Key="reactome_id" Value="9682385" />
  <Graphics BoardWidth="619.0" BoardHeight="273.0" />
  <DataNode TextLabel="Signaling by FLT3&#xA;ITD and TKD mutants" GraphId="da822" Type="Pathway">
    <Comment Source="Reactome">FLT3 is subject to internal tandem duplications (ITDs) of lengths varying from 3 to 1236 base pairs (Nakao et al, 1996; Kiyoi et al 1997, Meshinchi et al, 2008; reviewed in Kazi and Roonstrand, 2019). These ITDs are generally found in the juxtamembrane domain, or more rarely, the first tyrosine kinase domain (TKD) and disrupt the autoinhibitory loop of the receptor, constitutively activating it (Kiyoi et al, 2002; Griffith et al, 2004; reviewed in Lagunas-Rangel and Chavez-Valencia, 2017; Kazi and Roonstrand, 2019). FLT3 ITDs are found in ~25% of acute myeloid leukemias (AMLs) and represent the most frequent mutation of this cancer (reviewed in Kazi and Roonstrand, 2019, Klug et al, 2018)&lt;br&gt;At lower frequency, FLT3 is subject to activating point mutations (~7% of AML cases). These mutations tend to cluster in the TKD, with mutation of the activation loop residue D835 and the gatekeeper F691 residue the most common sites (Griffin et al, 2001; Jiang et al, 2004; reviewed in Kazi and Roonstrand, 2019). &lt;br&gt;FLT3 ITD and TKD mutants support cellular transformation through activation of downstream signaling pathways such as the MAP kinase, PI3K/AKT and STAT5 cascades. There is some debate about the extent to which the pathways activated by the ITD and TKD mutants are distinct, with some evidence that STAT5 signaling, in particular, is more characteristic of FLT3 ITD activation (Hayakawa et al, 2000; Choudhary et al, 2005; Grundler et al, 2005; Choudhary et al, 2007; Yoshimoto et al, 2009; Leischner et al, 2012; Janke et al, 2014; Marhall et al, 2018; reviewed in Chan, 2011; Kazi and Roonstrand, 2019).</Comment>
    <BiopaxRef>a6c</BiopaxRef>
    <BiopaxRef>e1d</BiopaxRef>
    <BiopaxRef>f52</BiopaxRef>
    <BiopaxRef>d3a</BiopaxRef>
    <BiopaxRef>a57</BiopaxRef>
    <BiopaxRef>e7b</BiopaxRef>
    <BiopaxRef>d64</BiopaxRef>
    <BiopaxRef>ecb</BiopaxRef>
    <BiopaxRef>ba9</BiopaxRef>
    <BiopaxRef>f0a</BiopaxRef>
    <BiopaxRef>e28</BiopaxRef>
    <BiopaxRef>d57</BiopaxRef>
    <BiopaxRef>be0</BiopaxRef>
    <BiopaxRef>d4f</BiopaxRef>
    <BiopaxRef>beb</BiopaxRef>
    <BiopaxRef>b2e</BiopaxRef>
    <BiopaxRef>a0e</BiopaxRef>
    <BiopaxRef>e17</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="102.5" CenterY="93.5" Width="179.0" Height="95.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9703648" />
  </DataNode>
  <DataNode TextLabel="Signaling by FLT3&#xA;fusion proteins" GraphId="afedd" Type="Pathway">
    <Comment Source="Reactome">In addition to internal tandem duplications and activating point mutations, FLT3 is also subject at low frequency to translocations that generate fusion proteins. These fusion proteins occur in some chronic myeloid leukemias as well as myeloid neoplasms with eosinophilia, and generate constitutively active proteins by virtue of fusing a N-terminal partner encoding a dimerization domain with the intracellular region of FLT3 (reviewed in Reiter and Gotlib, 2017; Kazi and Roonstrand, 2019). To date, 6 fusion partner genes of FLT3 have been identified: ETV6, TRIP11, MYO18A, SPTBN1, GOLGB1 and ZMYM2 (Balwin et al, 2007; Vu et al, 2006; Walz et al, 2011; Falchi et al, 2014; Chung et al, 2017; Troadec et al, 2017; Grand et al, 2007; Jawhar et al, 2017; Zhang et al, 2018).</Comment>
    <BiopaxRef>f44</BiopaxRef>
    <BiopaxRef>d3a</BiopaxRef>
    <BiopaxRef>fa1</BiopaxRef>
    <BiopaxRef>d9a</BiopaxRef>
    <BiopaxRef>f9d</BiopaxRef>
    <BiopaxRef>ce0</BiopaxRef>
    <BiopaxRef>cdb</BiopaxRef>
    <BiopaxRef>c24</BiopaxRef>
    <BiopaxRef>f21</BiopaxRef>
    <BiopaxRef>ae9</BiopaxRef>
    <BiopaxRef>afb</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="500.5" CenterY="96.0" Width="177.0" Height="92.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9703465" />
  </DataNode>
  <DataNode TextLabel="FLT3 mutants bind&#xA;TKIs" GraphId="ec58d" Type="Pathway">
    <Comment Source="Reactome">Aberrant signaling by activated forms of FLT3 can be inhibited by tyrosine kinase inhibitors (TKIs). FLT3 receptors are class III receptor tyrosine kinase receptors, also known as dual-switch. Dual-switch receptors are activated through a series of phosphorylation and conformational changes that move the receptor from the inactive form to the fully activated form. Type II TKIs bind to the inactive form of the receptor at a site adjacent to the ATP-binding cleft, while type I TKIs bind to the active form (reviewed in Klug et al, 2018; Daver et al, 2019).&lt;br&gt;&lt;br&gt;FLT3 internal tandem duplications (ITDs) are found in ~25-30% of acute myeloid leukemias, and are present at lower frequencies in other cancers (reviewed in Kazi and Roostrand, 2019; Patnaik et al, 2018). These ITDs generally occur in a tyrosine-rich region of exon 14, encoding the juxtamembrane domain region of the protein; at a lower frequency, ITDs are found in the first tyrosine kinase domain (TKD1). In addition to ITDs, a number of point mutations in the juxtamembrane domain have also been identified. Juxtamembrane domain mutations affect an autoinhibitory loop, shifting the equilibrium of the receptor towards the activated state; despite this, however, juxtamembrane domain mutants remain predominantly in the inactive state and as such are susceptible to inhibition by type II TKIs (reviewed in Patnaik et al, 2018; Kazi and Roonstrand et al, 2019). &lt;br&gt;&lt;br&gt;Activation loop mutations more strongly favor the active conformation of the receptor and are susceptible to inhibition by both type II and type I TKIs. The most prevalent FLT3 mutation, D835Y, promotes the active conformation strongly enough to be resistant to type II TKIs (Patnaik et al, 2017; Klug et al, 2018; Daver et al, 2019).</Comment>
    <BiopaxRef>d64</BiopaxRef>
    <BiopaxRef>d3a</BiopaxRef>
    <BiopaxRef>a5e</BiopaxRef>
    <BiopaxRef>cb8</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="104.5" CenterY="201.5" Width="175.0" Height="81.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9702509" />
  </DataNode>
  <DataNode TextLabel="Drug resistance of&#xA;FLT3 mutants" GraphId="b052c" Type="Pathway">
    <Comment Source="Reactome">FLT3 is mutated in ~30% of acute myeloid leukemias (AML), with internal tandem duplications (ITDs) representing the majority of these mutations and activating point mutants occurring at lower frequency. FLT3 mutations also occur at lower rates in other cancers (reviewed in Kazi and Roonstrand, 2018; Daver et al, 2019; Larroas-Garcia and Baer, 2017). Mutation of FLT3 has been identified as a driver in progression of AML and in consequence is a promising therapeutic target. A number of first and second generation inhibitors have been demonstrated to have activity against FLT3, but accumulation of secondary mutations leads to the development of resistance. These secondary mutations further shift the equilibrium of the receptor toward the activated state, making even the second-generation type II TKIs less effective. In consequence, considerable effort is devoted to discovery of type II and, in particular, type I TKIs that are active against highly activated FLT3 alleles (reviewed in Daver et al, 2019; Staudt et al, 2018; Lim et al, 2017; Klug et al, 2018).</Comment>
    <BiopaxRef>d3a</BiopaxRef>
    <BiopaxRef>a5e</BiopaxRef>
    <BiopaxRef>cbf</BiopaxRef>
    <BiopaxRef>f30</BiopaxRef>
    <BiopaxRef>e5e</BiopaxRef>
    <BiopaxRef>d64</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="298.5" CenterY="202.5" Width="173.0" Height="81.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9702506" />
  </DataNode>
  <DataNode TextLabel="FLT3 signaling by&#xA;CBL mutants" GraphId="b03ea" Type="Pathway">
    <Comment Source="Reactome">Missense and splicing mutants have been identified in the E3 ubiquitin ligase CBL in a number of cancers including acute and chronic myeloid leukemias, among others. These cancers show elevated signaling through FLT3 as a result of impaired CBL-mediated downregulation of the receptor (Sargin et al, 2007; Reindl et al, 2009; Caligiuri et al, 2007; Abbas et al, 2008).</Comment>
    <BiopaxRef>bcc</BiopaxRef>
    <BiopaxRef>cbc</BiopaxRef>
    <BiopaxRef>f1d</BiopaxRef>
    <BiopaxRef>add</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="301.5" CenterY="92.5" Width="173.0" Height="89.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9706377" />
  </DataNode>
  <InfoBox CenterX="0.0" CenterY="0.0" />
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d64">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">29964125</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Klug LR, Kent JD, Heinrich MC.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a5e">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">30651634</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Targeting FLT3 mutations in AML: review of current knowledge and evidence.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Daver N, Schlenk RF, Russell NH, Levis MJ.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="fca">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">12969963</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Zheng R, Levis M, Piloto O, Brown P, Baldwin BR, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, Small D.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cbf">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">30332834</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Staudt D, Murray HC, McLachlan T, Alvaro F, Enjeti AK, Verrills NM, Dun MD.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d3a">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">31066629</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Kazi JU, Rönnstrand L.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a6c">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">8946930</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e1d">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">9737679</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f52">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">14984498</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Stirewalt DL, Meshinchi S, Kussick SJ, Sheets KM, Pogosova-Agadjanyan E, Willman CL, Radich JP.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a57">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">14759363</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e7b">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28470536</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FLT3-ITD and its current role in acute myeloid leukaemia.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lagunas-Rangel FA, Chávez-Valencia V.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ecb">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">11290575</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Point mutations in the FLT3 gene in AML.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Griffin JD.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ba9">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">15178581</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, Gilliland DG, Meyerson M, Sellers WR.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f0a">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10698507</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e28">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">15769897</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Choudhary C, Schwäble J, Brandts C, Tickenbrock L, Sargin B, Kindler T, Fischer T, Berdel WE, Müller-Tidow C, Serve H.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d57">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">17356133</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Activation mechanisms of STAT5 by oncogenic Flt3-ITD.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Choudhary C, Brandts C, Schwable J, Tickenbrock L, Sargin B, Ueker A, Böhmer FD, Berdel WE, Müller-Tidow C, Serve H.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="be0">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">15718420</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Grundler R, Miething C, Thiede C, Peschel C, Duyster J.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d4f">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">19808698</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka K, Nagafuji K, Mizuno S, Niiro H, Gilliland GD, Akashi K.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="beb">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">22411868</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander S, Rönnstrand L, Götze K, Peschel C, Duyster J.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b2e">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">24608088</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, Berdel WE, Büchner T, Woermann BJ, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Polzer H.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a0e">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">29372308</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Marhäll A, Heidel F, Fischer T, Rönnstrand L.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e17">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">21359601</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chan PM.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f44">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28028030</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Myeloid neoplasms with eosinophilia.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Reiter A, Gotlib J.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="fa1">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">17268528</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Baldwin BR, Li L, Tse KF, Small S, Collector M, Whartenby KA, Sharkis SJ, Racke F, Huso D, Small D.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d9a">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">16761019</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Vu HA, Xinh PT, Masuda M, Motoji T, Toyoda A, Sakaki Y, Tokunaga K, Sato Y.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f9d">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">21705501</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Walz C, Erben P, Ritter M, Bloor A, Metzgeroth G, Telford N, Haferlach C, Haferlach T, Gesk S, Score J, Hofmann WK, Hochhaus A, Cross NC, Reiter A.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ce0">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">24854988</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, Luthra R, Popat U, Verstovsek S.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cdb">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">29025582</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chung A, Hou Y, Ohgami RS, Von Gehr A, Fisk DG, Roskin KM, Li X, Gojenola L, Bangs CD, Arber DA, Fire AZ, Cherry AM, Zehnder JL, Gotlib J, Merker JD.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c24">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">27795560</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Troadec E, Dobbelstein S, Bertrand P, Faumont N, Trimoreau F, Touati M, Chauzeix J, Petit B, Bordessoule D, Feuillard J, Bastard C, Gachard N.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f21">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">17764812</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Grand FH, Iqbal S, Zhang L, Russell NH, Chase A, Cross NC.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ae9">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28751768</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Jawhar M, Naumann N, Knut M, Score J, Ghazzawi M, Schneider B, Kreuzer KA, Hallek M, Drexler HG, Chacko J, Wallis L, Fabarius A, Metzgeroth G, Hofmann WK, Chase A, Tapper W, Reiter A, Cross NCP.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="afb">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">30559310</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Two myeloid leukemia cases with rare &lt;i&gt;FLT3&lt;/i&gt; fusions.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Zhang H, Paliga A, Hobbs E, Moore S, Olson S, Long N, Dao KT, Tyner JW.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cb8">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">29164965</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">The importance of FLT3 mutational analysis in acute myeloid leukemia.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Patnaik MM.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f30">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28851395</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Molecular targeting in acute myeloid leukemia.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lim SH, Dubielecka PM, Raghunathan VM.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e5e">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28576946</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Larrosa-Garcia M, Baer MR.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="bcc">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">17446348</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Flt3-dependent transformation by inactivating c-Cbl mutations in AML.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Sargin B, Choudhary C, Crosetto N, Schmidt MHH, Grundler R, Rensinghoff M, Thiessen C, Tickenbrock L, Schwäble J, Brandts C, August B, Koschmieder S, Bandi SR, Duyster J, Berdel WE, Müller-Tidow C, Dikic I, Serve H.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cbc">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">19276253</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Reindl C, Quentmeier H, Petropoulos K, Greif PA, Benthaus T, Argiropoulos B, Mellert G, Vempati S, Duyster J, Buske C, Bohlander SK, Humphries KR, Hiddemann W, Spiekermann K.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f1d">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">18698078</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Abbas S, Rotmans G, Löwenberg B, Valk PJ.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="add">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">17475912</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Caligiuri MA, Briesewitz R, Yu J, Wang L, Wei M, Arnoczky KJ, Marburger TB, Wen J, Perrotti D, Bloomfield CD, Whitman SP.</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>

